The use of consensus methods and expert panels in pharmacoeconomic studies: Practical applications and methodological shortcomings

PharmacoEconomics

Volumn 12, Issue 2, 1997, Pages 121-129

  Evans, Christopher ^a  

^a Lewin Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISEASE MANAGEMENT; EXPERIENCE; INFORMATION; MEDICAL DECISION MAKING; METHODOLOGY; PHARMACOECONOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 0030879624     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199712020-00003     Document Type: Article

References (44)

1. Kind P, Sorenson J. Modelling the cost-effectiveness of the prophylactic use of SSRIs in the treatment of depression. Int Clin Psychopharmacol 1995; 10 Suppl. 1: 41-8
2. Piccoli A, Puggia R, Fusaro M, et al. A decision analysis comparing three dosage regimens of subcutaneous epoetin in continuous ambulatory peritoneal dialysis. Pharmacoeconomics 1995; 7 (5): 444-56
3. Stewart A. Antidepressant pharmacotherapy: cost comparison of SSRIs and TCAs. Br J Med Econ 1994; 7: 67-79
4. Commonwealth Department of Health Housing and Community Services. Guidelines for the pharmaceutical industry on preparation of submissions to the pharmacy benefits advisory committee. Canberra: Australian Government Publishing House, 1992
5. Torrance G, Blaker D, Detsky A. Canadian guidelines for economic evaluation of pharmaceuticals. Pharmacoeconomics 1996; 9 (6): 535-59
6. Sackman H. Delphi critique: expert opinion, forecasting and group process; Lexington (MA): Lexington Books, 1975
7. Le Pen C, Levy E, Ravily V, et al. The cost of treatment dropout in depression: a cost benefit analysis of fluoxetine vs. tricyclics. J Affect Disord 1994; 31: 1-18
8. Reves R, Johnson P, Ericsson C, et al. A cost-effectiveness comparison of the use of antimicrobial agents for the treatment or prophylaxis of traveller's diarrhoea. Arch Intern Med 1988; 148: 2421-7
9. Williams S, Eisenberg JM, Pascale L, et al. Physicians' perceptions about unnecessary diagnostic testing. Inquiry 1982; 19: 363-70
10. Wong JB, Kokk R, Tine F, et al. Cost effectiveness of Interferon α2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122: 664-75
11. Revicki D, Brown R, Palmer W, et al. Modelling the cost effectiveness of antidepressant treatment in primary care. Pharmacoeconomics 1995; 8 (6): 524-40
12. Hatziandreu E, Brown R, Revicki D, et al. Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. Pharmacoeconomics 1994; 5 (3): 249-64
13. Simpson K, Hatziandreu E, Andersson F, et al. Cost effectiveness of antiviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300/μ1 in 5 European countries. Pharmacoeconomics 1994; 6 (6): 553-62
14. O'Brien B, Coeree R, Mohamed H, et al. Cost effectiveness of Heliobacter pylori eradication in the long-term management of duodenal ulcer in Canada. Arch Intern Med 1995; 155: 1958-64
15. Larrat EP. Cost effectiveness study of nitrate therapy using decision analysis methodology. Hosp Formul 1994; 29: 277-87
16. Pearson SD, Margolis C, Davis S, et al. Is consensus reproducible? A study of an algorithmic guideline development process. Med Care 1995; 33 (6): 643-60
17. Naylor DC, Baigrie R, Goldman B, et al. Assigning priority for patients requiring coronary revascularization: consensus principles from a panel of cardiologists and cardiac surgeons. Can J Cardiol 1991; 7 (5): 207-13
18. McDonnell J, Meijler A, Kahan J, et al. Panellist consistency in the assessment of medical appropriateness. Health Policy 1996; 139-52
19. Alexandrov A, Pullicino P, Meslin E, et al. Agreement on disease specific criteria for do-not-resuscitate orders in acute stroke. Stroke 1996; 27: 232-7
20. Brook R, Chassin M, Fink A. A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care 1986; 2: 53-64
21. Nuijten M, Hardens M, Souetre E. A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression. Pharmacoeconomics 1995; 8 (2): 159-68
22. Bentkover J, Feighner J. Cost analysis of paroxetine versus imipramine in major depression. Pharmacoeconomics 1995; 8 (3): 223-32
23. Craig AM, Davey P, Malek M, et al. Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin. Pharmacoeconomics 1996; 10 (1): 79-92
24. Martens L, Guibert R. Cost effectiveness analysis of lipid modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin Ther 1994; 16 (6): 1052-62
25. Einarson T, Arikian S, Sweeney S, et al. A model to evaluate the cost effectiveness of oral therapies in the management of patients with major depressive disorders. Clin Ther 1995; 17 (1): 136-53
26. Severo C, Fagnani F, Lafuma A. Cost effectiveness of hepatitis A prevention in France. Pharmacoeconomics 1995; 8 (1): 46-61
27. Shear N, Einarson T, Arikian S, et al. Pharmacoeconomic analysis of topical treatments for tinea infections. Pharmacoeconomics 1995; 7 (3): 251-67
28. Marchetti A, Piech CT, McGhan W, et al. Pharmacoeconomic analysis of oral therapies for onychomycosis: a US model. Clin Ther 1996; 18 (4): 757-77
29. Jonsson B, Bebbington P. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 164: 665-73
30. Dittus R, Roberts S, Adolph R. Cost-effectiveness analysis of patient management alternatives after uncomplicated myocardial infarction: a model. J Am Coll Cardiol 1987; 10: 869-78
31. Dittus R, Roberts S, Adolph J, et al. Cost-effective management of patients following myocardial infarction: the impact of ischemia on alternative approaches. PACE 1988; 11: 2086-92
32. Imperiale T, Speroff T, Cebul R, et al. A cost analysis of alternative treatments for duodenal ulcer. Ann Intern Med 1995; 123: 665-72
33. Bloom B, Hillman A, Fendrick M, et al. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis. Ann Intern Med 1993; 118: 298-306
34. Lurie P, Avins A, Phillips K, et al. The cost-effectiveness of voluntary counseling and testing of hospital inpatients for HIV infection. JAMA 1994; 272 (23): 1832-8
35. Phillips K, Lowe R, Kahn J. The cost-effectiveness of HIV testing of physicians and dentists in the United States. JAMA 1994; 271 (11): 851-8
36. Begley C, Annegers J, Lairson D, et al. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia 1994; 35 (6): 1230-43
37. Field M, Lohr K. Guidelines for clinical practice: from development to use. Washington (DC): National Academy Press, 1992
38. Jariath N, Weinstein J. The Delphi methodology: a useful administrative approach. Can J Nurs Adm 1994; 7 (4 Pt 2): 7-20
39. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995; 311: 376-80
40. Jariath N, Weinstein J. The Delphi methodology: a useful administrative approach. Can J Nurs Adm 1994, 7 (3 Pt 1): 29-42
41. Gruber M. The development of a position statement using the Delphi technique. Gastoenterol Nurs 1993 Oct: 68-71
42. Barr J, Schumacher G. Using decision analysis to conduct pharmacoeconomic studies. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996: 1197-214
43. Williams P, Webb C. The Delphi technique: a methodological discussion. J Adv Nurs 1994; 19: 180-6
44. Vermeulen L, Ratko T, Erstad B, et al. A paradigm of consensus: the University Hospital Consortium guidelines for the use of albumin nonprotein colloid and crystalloid solutions. Arch Intern Med 1995; 155: 373-9